Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

NCT01350817 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.

NCT NCT01350817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01350817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Lead sponsor
University Hospital, Limoges
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
January 31, 2014
Enrollment
156 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer